The safety of statins in clinical practice

[1]  J. McMurray,et al.  Statins and chronic heart failure: do we need a large-scale outcome trial? , 2002, Journal of the American College of Cardiology.

[2]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[3]  R. Paoletti,et al.  Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions , 2004, Circulation.

[4]  R. Collins,et al.  Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. , 1995, The British journal of ophthalmology.

[5]  G. Fonarow,et al.  Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. , 2002, Journal of cardiac failure.

[6]  C. Ballantyne,et al.  Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). , 2003, American heart journal.

[7]  M. Madariaga.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[8]  H. Krum,et al.  Should patients with chronic heart failure be treated with "statins"? , 2003, Heart failure monitor.

[9]  R. Collins,et al.  Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group. , 1996, British journal of clinical pharmacology.

[10]  M. Muenke,et al.  Central nervous system and limb anomalies in case reports of first-trimester statin exposure. , 2004, The New England journal of medicine.

[11]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[12]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[13]  S. von Haehling,et al.  Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? , 2004, Heart.

[14]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[15]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. , 1994, The American journal of cardiology.

[16]  Y. Arad,et al.  Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. , 1992, Metabolism: clinical and experimental.

[17]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[18]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[19]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[20]  G. Moneta.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions Heart , 2022 .

[21]  T. A. Jacobson,et al.  Statin safety: lessons from new drug applications for marketed statins. , 2006, The American journal of cardiology.

[22]  G. Thorgeirsson,et al.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.

[23]  R. Collins,et al.  N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. , 2007, Journal of the American College of Cardiology.

[24]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[25]  H. Silbershatz,et al.  Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. , 2003, The American journal of cardiology.

[26]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[27]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.

[28]  M. Landray,et al.  Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials , 2004, Current opinion in nephrology and hypertension.

[29]  B. Davis,et al.  Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project , 2002, Circulation.

[30]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[31]  H. Hutchinson,et al.  Rosuvastatin-Induced Arrest in Progression of Renal Disease , 2004, Cardiology.

[32]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[33]  R. Peto,et al.  Diet life-style and mortality in China: a study of the characteristics of 65 Chinese counties. , 1990 .

[34]  J. Fox,et al.  Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme™ , 2004, Expert opinion on pharmacotherapy.

[35]  K. Tolman.  The liver and lovastatin. , 2002, The American journal of cardiology.

[36]  P. Libby,et al.  Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study , 2004, Circulation.

[37]  Stuart Donnan,et al.  Diet, Life-Style and Mortality in China , 1992 .

[38]  N. Wald,et al.  Safety of cholesterol reduction remains in doubt , 1994 .

[39]  T. Sakaeda,et al.  Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport , 2005, Pharmaceutical Research.

[40]  G. Thorgeirsson,et al.  Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. , 1996, Archives of internal medicine.

[41]  A. Scialli,et al.  Statin drugs and congenital anomalies , 2005, American journal of medical genetics. Part A.

[42]  J. Hallas,et al.  Statins and risk of polyneuropathy: A case-control study , 2002, Neurology.

[43]  M. Mercuri,et al.  Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial With Simvastatin , 2002, Circulation.

[44]  E. Stein,et al.  Sleep disturbance and HMG CoA reductase inhibitors. , 1990, JAMA.

[45]  I. Reid,et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial , 2001, The Lancet.

[46]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[47]  J. Pasco,et al.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. , 2002, Archives of internal medicine.

[48]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[49]  P. Doraiswamy,et al.  Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature , 2003, Pharmacotherapy.

[50]  Bertram Pitt,et al.  Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.

[51]  F. Sacks,et al.  Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. , 2003, Journal of the American Society of Nephrology : JASN.

[52]  J. Tsai,et al.  Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. , 2006, The American journal of cardiology.

[53]  G. Melli,et al.  Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients , 2005, Medicine.

[54]  R. Lane,et al.  Rhabdomyolysis , 2003, BMJ : British Medical Journal.

[55]  L. Palinkas,et al.  Plasma cholesterol and depressive symptoms in older men , 1993, The Lancet.

[56]  R. Collins,et al.  CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT , 1985 .

[57]  S. Manuck,et al.  Ischaemic heart disease and cholesterol Safety of cholesterol reduction remains in doubt , 1994, BMJ.

[58]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. , 1991, The American journal of medicine.

[59]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[60]  John A. Clark,et al.  Statin safety: an appraisal from the adverse event reporting system. , 2006, American Journal of Cardiology.

[61]  T. Pedersen,et al.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. , 1996, Drug safety.

[62]  R. Collins.  CHOLESTEROL LOWERING TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT , 1993 .

[63]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[64]  R. Califf,et al.  A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 , 2006, Circulation.

[65]  Mark A. Creager,et al.  Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease , 2003, Circulation.

[66]  David Colquhoun,et al.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.

[67]  B. Kasiske,et al.  Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.

[68]  D. Waters,et al.  Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.

[69]  T. Pickering,et al.  Statin use in heart failure: a cause for concern? , 2006, American heart journal.

[70]  R. Karas,et al.  The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis , 2005, Circulation.

[71]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.

[72]  E. Varol,et al.  Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention. , 2006, The American journal of cardiology.

[73]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[74]  P. Hopkins,et al.  Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. , 1999, JAMA.

[75]  L. Wise,et al.  The role of maternal toxicity in lovastatin-induced developmental toxicity. , 2004, Birth defects research. Part B, Developmental and reproductive toxicology.

[76]  E. Simonsick,et al.  Low cholesterol concentrations and severe depressive symptoms in elderly people , 1994, BMJ.

[77]  C. Ashton,et al.  Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. , 1994, British journal of clinical pharmacology.

[78]  J. Rindone,et al.  Experience with statin use in patients with chronic hepatitis C infection. , 2005, The American journal of cardiology.

[79]  S. Anker,et al.  The relationship between cholesterol and survival in patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[80]  A. Goldberg,et al.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.

[81]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.

[82]  B. Ma,et al.  Mechanistic studies on metabolic interactions between gemfibrozil and statins. , 2002, The Journal of pharmacology and experimental therapeutics.

[83]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[84]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[85]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[86]  J. Tobert,et al.  Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.

[87]  M. Mercuri,et al.  A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. , 2001, Current medical research and opinion.

[88]  J. Kastelein,et al.  Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[89]  K. Tolman,et al.  Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.

[90]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[91]  B. McCrindle,et al.  Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. , 2003, The Journal of pediatrics.

[92]  A. Alberts,et al.  On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. , 1990, Experimental eye research.

[93]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[94]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[95]  淳一 佐々木.  Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[96]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[97]  Diabetes Uk,et al.  JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .

[98]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[99]  N. Kaplowitz,et al.  Serum alanine aminotransferase in skeletal muscle diseases , 2005, Hepatology.

[100]  R Peto,et al.  Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.

[101]  M. Tonelli,et al.  Statins for improving renal outcomes: a meta-analysis. , 2006, Journal of the American Society of Nephrology : JASN.

[102]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[103]  J. Gibbs,et al.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice , 2005, Heart.

[104]  H. Taylor,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. , 1991, The American journal of cardiology.

[105]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[106]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[107]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[108]  R. Collins,et al.  Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration , 1996, BMJ.

[109]  Sungha Park,et al.  A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. , 2005, Clinical therapeutics.

[110]  S. Manuck,et al.  Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials , 2001, BMJ : British Medical Journal.

[111]  T. Pedersen,et al.  Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease , 1996 .

[112]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[113]  S. Grundy.  The issue of statin safety: where do we stand? , 2005, Circulation.

[114]  R. Collins,et al.  Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. , 1994, European heart journal.

[115]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[116]  M. Brown,et al.  Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. , 1980, Journal of lipid research.

[117]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[118]  H. Taylor,et al.  The human lens after 48 weeks of treatment with lovastatin. , 1990, The New England journal of medicine.

[119]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[120]  A. Hartmann,et al.  Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[121]  M. Cunningham,et al.  Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[122]  I. Reid,et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. , 2001, Lancet.

[123]  H. Brewer,et al.  Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. , 2003, The American journal of cardiology.

[124]  W. Maddrey.  Drug-induced hepatotoxicity: 2005. , 2005, Journal of clinical gastroenterology.

[125]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .

[126]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.